Alnylam Pharmaceuticals' Net Income rose 325.05% to $251.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.6 million, marking a year-over-year increase of 113.11%. This contributed to the annual value of -$278.2 million for FY2024, which is 36.82% up from last year.
According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' Net Income is $251.1 million, which was up 478.84% from -$66.3 million recorded in Q2 2025.
Alnylam Pharmaceuticals' Net Income's 5-year high stood at $251.1 million during Q3 2025, with a 5-year trough of -$405.9 million in Q3 2022.
For the 3-year period, Alnylam Pharmaceuticals' Net Income averaged around -$53.7 million, with its median value being -$66.3 million (2025).
Data for Alnylam Pharmaceuticals' Net Income shows a peak YoY increase of 325.05% (in 2025) and a maximum YoY decrease of 292.43% (in 2025) over the last 5 years.
Quarterly analysis of 5 years shows Alnylam Pharmaceuticals' Net Income stood at -$258.5 million in 2021, then grew by 19.72% to -$207.5 million in 2022, then surged by 33.55% to -$137.9 million in 2023, then soared by 39.24% to -$83.8 million in 2024, then soared by 325.05% to $251.1 million in 2025.
Its Net Income was $251.1 million in Q3 2025, compared to -$66.3 million in Q2 2025 and -$57.5 million in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value